Psyence BioMed launches psilocybin longevity research program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Psyence BioMed launches psilocybin longevity research program

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

November 25, 2025 7:00 AM EST

First publicly listed company to actively investigate psilocybins potential impact on longevity

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (Psyence BioMed or the Company), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first and currently the only publicly listed company to investigate psilocybins potential impact on biological markers associated with aging and longevity.... More